Literature DB >> 25934909

Nonalcoholic fatty liver disease.

Steven Fusillo1, Bryan Rudolph2.   

Abstract

On the basis of strong research and consensus, nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in children and is soon to be the most common indication for liver transplantation in adults. Although the disease begins as simple steatosis, some patients may progress to nonalcoholic steatohepatitis (NASH) and cirrhosis, making early identification and treatment critical.• The diagnosis of NAFLD can be challenging because patients are typically asymptomatic, with no major clinical symptoms of liver disease. Overweight and obese children are at the highest risk for disease. (1)(2)• On the basis of moderate research and consensus, serum ALT is usually mildly elevated but is an imperfect test with a low sensitivity for detecting NAFLD at commonly used thresholds.(10) Liver biopsy is still considered the gold standard for diagnosis but is too invasive for population-level screening and is often used selectively. Novel, noninvasive diagnostic modalities and serum biomarkers are currently being studied but warrant further validation, especially in children.• On the basis of moderate research and consensus, assessing serum liver tests in any overweight or obese child is reasonable.Liver disease should be suspected if the serum ALT is ‡22 U/L(0.37 mkat/L) in girls and ‡25 U/L (0.42 mkat/L) in boys. (10)Subspecialist referral should be considered for those with a normal BMI, persistent ALT elevation longer than 6 months,specific symptoms of advanced liver disease such as splenomegaly, or concerning laboratory findings on selected screening tests.• On the basis of strong research evidence, weight loss is the most efficacious treatment for NAFLD.• On the basis of some research and consensus, initiation of vitamin E therapy (400 IU BID) may be started, although its use probably should be restricted to those children with biopsy-proven disease. (12)• On the basis of some research and consensus, novel elastography-based imaging modalities are being studied in children and several drugs show promise in treating NAFLD.

Entities:  

Mesh:

Year:  2015        PMID: 25934909     DOI: 10.1542/pir.36-5-198

Source DB:  PubMed          Journal:  Pediatr Rev        ISSN: 0191-9601


  5 in total

1.  Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.

Authors:  Seyed Ali Jazayeri-Tehrani; Seyed Mahdi Rezayat; Siavash Mansouri; Mostafa Qorbani; Seyed Moayed Alavian; Milad Daneshi-Maskooni; Mohammad-Javad Hosseinzadeh-Attar
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

2.  Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: a whole trancriptome study by RNA-Seq.

Authors:  Mingzhe Zhu; Shijun Hao; Tao Liu; Lili Yang; Peiyong Zheng; Li Zhang; Guang Ji
Journal:  Oncotarget       Date:  2017-07-28

Review 3.  Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.

Authors:  Cong Liu; Jia-Zhi Liao; Pei-Yuan Li
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

4.  Interventions to improve liver enzyme screening testing in obese patients aged <18 years in a public hospital, Chicago, IL, 2017-2018.

Authors:  Megan Ward; Peter Nguyen; Simi Akintorin; Rosibell Arcia; Kenneth Soyemi
Journal:  Pediatric Health Med Ther       Date:  2018-12-19

5.  Prevalence and risk factors of elevated alanine aminotransferase among Korean adolescents: 2001-2014.

Authors:  Ju Whi Kim; Kyung Jae Lee; Hye Ran Yang; Ju Young Chang; Jin Soo Moon; Young-Ho Khang; Jae Sung Ko
Journal:  BMC Public Health       Date:  2018-05-11       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.